Ted Fjallman, CEO of Prokarium
Dr Ted Fjallman is the CEO of Prokarium, a London-based biotech focusing on targeted oral vaccines and microbial immunotherapy. Prior to joining Prokarium, Ted held a clinical research position at Sahlgrenska University Hospital and has worked as a strategy consultant at Sweden’s Royal Academy of Engineering Sciences, where he coordinated the country’s national innovation strategy. He is also committed to promoting science and innovation in society and in 2009 Ted became one of the 45 finalists out of 8300 European Astronaut Selection candidates.
Ted holds a PhD from the University of Guelph, Canada, and has been recognised as a leader in biotechnology under the Sloan Foundation funded Synthetic Biology Leadership Accelerator Program (LEAP). He is a member of the international Bacterial Vaccines Network (BactiVac) management board, as well as an active member in the UK BioIndustry Association (BIA).
Prokarium is a venture-backed biotech company with programmes focused on global health and innovation including vaccines against enter fever, Chlamydia trachomatis and Yersinia pestis, the latter being developed with the UK government. The synthetic biology platform, which has been safely tested in 10 clinical trials in 471 volunteers, is also being evaluated as a microbial immunotherapy targeting technology for solid tumours.